Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors

ABSTRACT Thymic epithelial cells give rise to both thymoma and thymic carcinoma. A crucial advance in thymic epithelial tumors (TET) management may derive from the identification of novel molecular biomarkers able to improve diagnosis, prognosis and treatment planning.In a previous study, we identified microRNAs that were differentially expressed in tumor vs normal thymic tissues. Among the microRNAs resulted up-regulated in TET tissues, we evaluated miR-21-5p, miR-148a-3p, miR-141-3p, miR-34b-5p, miR-34c-5p, miR-455-5p as blood plasma circulating non-invasive biomarkers for TET management.We firstly report that the expression levels of specific onco-miRNAs, that we found upregulated in the blood plasma collected from TET patients at surgery, resulted significantly reduced in follow-up samples.This pilot study suggests that circulating miR-21-5p and miR-148a-3p could represent novel non-invasive biomarkers to evaluate the efficacy of therapy and the prognosis of TET.

[1]  H. Matsuda,et al.  The World Health Organization histologic classification system reflects the oncologic behavior of thymoma , 2002, Cancer.

[2]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[3]  E. Ruffini,et al.  World Health Organization histologic classification: an independent prognostic factor in resected thymomas. , 2005, Lung cancer.

[4]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[5]  N. Girard.  Thymic Tumors: Relevant Molecular Data in the Clinic , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  F. Venuta,et al.  Thymoma and thymic carcinoma. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[8]  M. Nykter,et al.  Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis , 2011, PloS one.

[9]  Yi-Song Wang,et al.  Thymic malignancies: from clinical management to targeted therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Fontemaggi,et al.  MicroRNAs and lymph node metastatic disease in lung cancer. , 2012, Thoracic surgery clinics.

[11]  G. Yousef,et al.  Clinical evaluation of microRNA expression profiling in non small cell lung cancer. , 2013, Lung cancer.

[12]  N. Girard,et al.  ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  M. Gong,et al.  Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma , 2014, Tumor Biology.

[14]  F. Venuta,et al.  MicroRNA expression profiling of thymic epithelial tumors. , 2014, Lung cancer.

[15]  P. Muti,et al.  Tumor suppressor microRNAs: A novel non‐coding alliance against cancer , 2014, FEBS letters.

[16]  F. Venuta,et al.  Management of thymic tumors: a European perspective. , 2014, Journal of thoracic disease.

[17]  A. Nicholson,et al.  [The Masaoka-Koga stage classification for thymic malignancies clarification and definition of terms]. , 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.